Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a descriptive pilot study on a ready-constituted biobank (outside the Jardé Law). It is an ancillary study to the "GrossPath" cohort (RCB ID number: 2014-A01120-47).
Pregnancy generates an increased risk of thrombosis, and placenta-mediated diseases constitute a risk factor for cardiovascular pathologies responsible for significant maternal-fetal morbidity and mortality. Understanding and exploring the cellular and molecular mechanisms of dysfunctions of the vascular-placental interface could provide arguments to understand the systemic vascular risk, characterize it and finally detect it on the basis of new markers, thus opening the way for targeted preventive management to reinforce the general principles of precision medicine.
Netosis is a process of activation of neutrophils, which then generate filaments containing DNA, enzymes and extracellular histones. Netosis occurs in pregnancy and is increased in vascular-placental complications. It can be studied by measuring circulating histones, particularly the citrullinated histone H3. Levels of this modified histone H3, as well as those of two other modifications, have recently been shown to increase during pregnancy. These levels have also been shown to be even greater in pregnancy complications.
The aim of this study is to complete this mapping in order to obtain a precise signature for all post-translational histone modifications in normal pregnancies and pregnancies complicated by pre-eclampsia from the "GrossPath" cohort in order to propose new circulating biomarkers for placental vascular pathologies.
The post-translational histone modification profiles (mapping) of pregnant women with normal pregnancies will be compared with those developing pre-eclampsia.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Plasma from women with normal pregnancies | Plasma collected from women with normal pregnancies will be analyzed by mass spectrometry |
| |
| Plasma from women with placenta-mediated complications | Plasma collected from women who developed preeclampsia during pregnancy will be analyzed by mass spectrometry |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Analysis of post-translational histone modifications via mass spectrometry | Diagnostic Test | During the "GrossHist" study (NCT04205383), only 3 post-translational histone modifications available in ELISA at the time were quantified thanks to a collaboration with the VOLITIONâ„¢ company [Bouvier and Fortier et al. 2021]. The development of a new mass spectrometry approach based on nucleosome enrichment of plasma, developed by collaborators at VOLITIONâ„¢, has made it possible to consider the description of all post-translational histone modifications (about 40 post-translational modifications involving histones H2A, H2B, H3 and H4). |
| Measure | Description | Time Frame |
|---|---|---|
| Presence of methylation in histone H2A in pregnant women with normal pregnancies | Mass spectrometry will be used to detect the presence or not of methylation in histone H2A and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of methylation in histone H2A in pregnant women developing pre-eclampsia | Mass spectrometry will be used to detect the presence or not of methylation in histone H2A and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of methylation in histone H2B in pregnant women with normal pregnancies | Mass spectrometry will be used to detect the presence or not of methylation in histone H2B and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of methylation in histone H2B in pregnant women developing pre-eclampsia | Mass spectrometry will be used to detect the presence or not of methylation in histone H2B and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of methylation in histone H3 in pregnant women with normal pregnancies | Mass spectrometry will be used to detect the presence or not of methylation in histone H3 and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of methylation in histone H3 in pregnant women developing pre-eclampsia | Mass spectrometry will be used to detect the presence or not of methylation in histone H3 and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Measure | Description | Time Frame |
|---|---|---|
| Intensity of methylation in histone H2A in pregnant women with normal pregnancies | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of methylation in histone H2A in pregnant women developing pre-eclampsia |
Not provided
Inclusion Criteria:
Exclusion Criteria:
The study is based on frozen plasma samples from pregnant women, taken at the time of them giving birth from among the 50 women who constituted the GrossPath cohort. Fourteen of these women had had normal pregnancies and fourteen had developed pre-eclampsia. Cases are matched on maternal age, clinical event (delivery) and gestational age will be included from the GrossPath cohort.
Not provided
The study is based on frozen plasma samples from pregnant women, taken at the time of them giving birth from among the 50 women who constituted the GrossPath cohort. Fourteen of these women had had normal pregnancies and fourteen had developed pre-eclampsia. Cases are matched on maternal age, clinical event (delivery) and gestational age will be included from the GrossPath cohort.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sylvie BOUVIER, Dr. | Nîmes University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nîmes University Hospital | Nîmes | Gard | 30900 | France |
All data collection and management will be carried out by the BESPIM (Biostatistique, Epidémiologie clinique, Santé Publique & Innovation en Méthodologie).
The conditions of transfer of all or part of the research database are decided by the principal investigator and the research sponsor and are the subject of a written contract.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is based on the mass spectrometric analysis of frozen plasma samples from patients included in the "GrossPath" cohort (BCR ID: 2014-A01120-47). The benefits will ultimately be a better understanding of the physiopathological mechanisms involved in the occurrence of this placental vascular pathology.
|
| Presence of methylation in histone H4 in pregnant women with normal pregnancies | Mass spectrometry will be used to detect the presence or not of methylation in histone H4 and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of methylation in histone H4 in pregnant women developing pre-eclampsia | Mass spectrometry will be used to detect the presence or not of methylation in histone H4 and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of acetylation in histone H2A in pregnant women with normal pregnancies | Mass spectrometry will be used to detect the presence or not of acetylation in histone H2A and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of acetylation in histone H2A in pregnant women developing pre-eclampsia | Mass spectrometry will be used to detect the presence or not of acetylation in histone H2A and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of acetylation in histone H2B in pregnant women with normal pregnancies | Mass spectrometry will be used to detect the presence or not of acetylation in histone H2B and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of acetylation in histone H2B in pregnant women developing pre-eclampsia | Mass spectrometry will be used to detect the presence or not of acetylation in histone H2B and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of acetylation in histone H3 in pregnant women with normal pregnancies | Mass spectrometry will be used to detect the presence or not of acetylation in histone H3 and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of acetylation in histone H3 in pregnant women developing pre-eclampsia | Mass spectrometry will be used to detect the presence or not of acetylation in histone H3 and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of acetylation in histone H4 in pregnant women with normal pregnancies | Mass spectrometry will be used to detect the presence or not of acetylation in histone H4 and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of acetylation in histone H4 in pregnant women developing pre-eclampsia | Mass spectrometry will be used to detect the presence or not of acetylation in histone H4 and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of phosphorylation in histone H2A in pregnant women with normal pregnancies | Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H2A and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of phosphorylation in histone H2A in pregnant women developing pre-eclampsia | Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H2A and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of phosphorylation in histone H2B in pregnant women with normal pregnancies | Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H2B and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of phosphorylation in histone H2B in pregnant women developing pre-eclampsia | Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H2B and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of phosphorylation in histone H3 in pregnant women with normal pregnancies | Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H3 and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of phosphorylation in histone H3 in pregnant women developing pre-eclampsia | Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H3 and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of phosphorylation in histone H4 in pregnant women with normal pregnancies | Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H4 and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of phosphorylation in histone H4 in pregnant women developing pre-eclampsia | Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H4 and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of ubiquitination in histone H2A in pregnant women with normal pregnancies | Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H2A and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of ubiquitination in histone H2A in pregnant women developing pre-eclampsia | Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H2A and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of ubiquitination in histone H2B in pregnant women with normal pregnancies | Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H2B and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of ubiquitination in histone H2B in pregnant women developing pre-eclampsia | Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H2B and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of ubiquitination in histone H3 in pregnant women with normal pregnancies | Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H3 and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of ubiquitination in histone H3 in pregnant women developing pre-eclampsia | Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H3 and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of ubiquitination in histone H4 in pregnant women with normal pregnancies | Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H4 and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of ubiquitination in histone H4 in pregnant women developing pre-eclampsia | Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H4 and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of citrullination in histone H2A in pregnant women with normal pregnancies | Mass spectrometry will be used to detect the presence or not of citrullination in histone H2A and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of citrullination in histone H2A in pregnant women developing pre-eclampsia | Mass spectrometry will be used to detect the presence or not of citrullination in histone H2A and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of citrullination in histone H2B in pregnant women with normal pregnancies | Mass spectrometry will be used to detect the presence or not of citrullination in histone H2B and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of citrullination in histone H2B in pregnant women developing pre-eclampsia | Mass spectrometry will be used to detect the presence or not of citrullination in histone H2B and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of citrullination in histone H3 in pregnant women with normal pregnancies | Mass spectrometry will be used to detect the presence or not of citrullination in histone H3 and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of citrullination in histone H3 in pregnant women developing pre-eclampsia | Mass spectrometry will be used to detect the presence or not of citrullination in histone H3 and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of citrullination in histone H4 in pregnant women with normal pregnancies | Mass spectrometry will be used to detect the presence or not of citrullination in histone H4 and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
| Presence of citrullination in histone H4 in pregnant women developing pre-eclampsia | Mass spectrometry will be used to detect the presence or not of citrullination in histone H4 and recorded as YES/NO. | At pregnancy term (max 41 weeks gestation) |
Mass spectrometry, quantitative
| At pregnancy term (max 41 weeks gestation) |
| Intensity of methylation in histone H2B in pregnant women with normal pregnancies | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of methylation in histone H2B in pregnant women developing pre-eclampsia | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of methylation in histone H3 in pregnant women with normal pregnancies | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of methylation in histone H3 in pregnant women developing pre-eclampsia | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of methylation in histone H4 in pregnant women with normal pregnancies | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of methylation in histone H4 in pregnant women developing pre-eclampsia | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of acetylation in histone H2A in pregnant women with normal pregnancies | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of acetylation in histone H2A in pregnant women developing pre-eclampsia | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of acetylation in histone H2B in pregnant women with normal pregnancies | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of acetylation in histone H2B in pregnant women developing pre-eclampsia | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of acetylation in histone H3 in pregnant women with normal pregnancies | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of acetylation in histone H3 in pregnant women developing pre-eclampsia | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of acetylation in histone H4 in pregnant women with normal pregnancies | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of acetylation in histone H4 in pregnant women developing pre-eclampsia | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of phosphorylation in histone H2A in pregnant women with normal pregnancies | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of phosphorylation in histone H2A in pregnant women developing pre-eclampsia | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of phosphorylation in histone H2B in pregnant women with normal pregnancies | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of phosphorylation in histone H2B in pregnant women developing pre-eclampsia | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of phosphorylation in histone H3 in pregnant women with normal pregnancies | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of phosphorylation in histone H3 in pregnant women developing pre-eclampsia | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of phosphorylation in histone H4 in pregnant women with normal pregnancies | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of phosphorylation in histone H4 in pregnant women developing pre-eclampsia | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of ubiquitination in histone H2A in pregnant women with normal pregnancies | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of ubiquitination in histone H2A in pregnant women developing pre-eclampsia | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of ubiquitination in histone H2B in pregnant women with normal pregnancies | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of ubiquitination in histone H2B in pregnant women developing pre-eclampsia | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of ubiquitination in histone H3 in pregnant women with normal pregnancies | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of ubiquitination in histone H3 in pregnant women developing pre-eclampsia | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of ubiquitination in histone H4 in pregnant women with normal pregnancies | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of ubiquitination in histone H4 in pregnant women developing pre-eclampsia | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of citrullination in histone H2A in pregnant women with normal pregnancies | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of citrullination in histone H2A in pregnant women developing pre-eclampsia | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of citrullination in histone H2B in pregnant women with normal pregnancies | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of citrullination in histone H2B in pregnant women developing pre-eclampsia | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of citrullination in histone H3 in pregnant women with normal pregnancies | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of citrullination in histone H3 in pregnant women developing pre-eclampsia | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of citrullination in histone H4 in pregnant women with normal pregnancies | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Intensity of citrullination in histone H4 in pregnant women developing pre-eclampsia | Mass spectrometry, quantitative | At pregnancy term (max 41 weeks gestation) |
| Presence of methylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | YES/NO | Before 34 weeks of pregnancy |
| Presence of methylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | YES/NO | 34 to 41 weeks of pregnancy |
| Presence of methylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | YES/NO | Before 34 weeks of pregnancy |
| Presence of methylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | YES/NO | 34 to 41 weeks of pregnancy |
| Presence of methylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | YES/NO | Before 34 weeks of pregnancy |
| Presence of methylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | YES/NO | 34 to 41 weeks of pregnancy |
| Presence of methylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | YES/NO | Before 34 weeks of pregnancy |
| Presence of methylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | YES/NO | 34 to 41 weeks of pregnancy |
| Presence of acetylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | YES/NO | Before 34 weeks of pregnancy |
| Presence of acetylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | YES/NO | 34 to 41 of pregnancy |
| Presence of acetylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | YES/NO | Before 34 weeks of pregnancy |
| Presence of acetylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | YES/NO | 34 to 41 weeks of pregnancy |
| Presence of acetylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | YES/NO | Before 34 weeks of pregnancy |
| Presence of acetylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | YES/NO | After 34 weeks of pregnancy |
| Presence of acetylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | YES/NO | Before 34 weeks of pregnancy |
| Presence of acetylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | YES/NO | 34 to 41 weeks of pregnancy |
| Presence of phosphorylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | YES/NO | Before 34 weeks of pregnancy |
| Presence of phosphorylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | YES/NO | 34 to 41 weeks of pregnancy |
| Presence of phosphorylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | YES/NO | Before 34 weeks of pregnancy |
| Presence of phosphorylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | YES/NO | 34 to 41 weeks of pregnancy |
| Presence of phosphorylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | YES/NO | Before 34 weeks of pregnancy |
| Presence of phosphorylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | YES/NO | 34 to 41 weeks of pregnancy |
| Presence of phosphorylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | YES/NO | Before 34 weeks of pregnancy |
| Presence of phosphorylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | YES/NO | 34 to 41 weeks of pregnancy |
| Presence of ubiquitination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | YES/NO | Before 34 weeks of pregnancy |
| Presence of ubiquitination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | YES/NO | 34 to 41 weeks of pregnancy |
| Presence of ubiquitination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | YES/NO | Before 34 weeks of pregnancy |
| Presence of ubiquitination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | YES/NO | 34 to 41 weeks of pregnancy |
| Presence of ubiquitination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | YES/NO | Before 34 weeks of pregnancy |
| Presence of ubiquitination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | YES/NO | 34 to 41 weeks of pregnancy |
| Presence of ubiquitination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | YES/NO | Before 34 weeks of pregnancy |
| Presence of ubiquitination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | YES/NO | 34 to 41 weeks of pregnancy |
| Presence of citrullination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | YES/NO | Before 34 weeks of pregnancy |
| Presence of citrullination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | YES/NO | 34 to 41 weeks of pregnancy |
| Presence of citrullination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | YES/NO | Before 34 weeks of pregnancy |
| Presence of citrullination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | YES/NO | 34 to 41 weeks of pregnancy |
| Presence of citrullination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | YES/NO | Before 34 weeks of pregnancy |
| Presence of citrullination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | YES/NO | 34 to 41 weeks of pregnancy |
| Presence of citrullination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | YES/NO | Before 34 weeks of pregnancy |
| Presence of citrullination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | YES/NO | 34 to 41 weeks of pregnancy |
| Intensity of methylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of methylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | Mass spectrometry, quantitative | 34 to 41 weeks of pregnancy |
| Intensity of methylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of methylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | Mass spectrometry, quantitative | 34 to 41 weeks of pregnancy |
| Intensity of methylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of methylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | Mass spectrometry, quantitative | 34 to 41 weeks of pregnancy |
| Intensity of methylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of methylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | Mass spectrometry, quantitative | 34 to 41 weeks of pregnancy |
| Intensity of acetylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of acetylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | Mass spectrometry, quantitative | 34 to 41 weeks of pregnancy |
| Intensity of acetylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of acetylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | Mass spectrometry, quantitative | 34 to 41 weeks of pregnancy |
| Intensity of acetylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of acetylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | Mass spectrometry, quantitative | 34 to 41 weeks of pregnancy |
| Intensity of acetylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of acetylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | Mass spectrometry, quantitative | 34 to 41 weeks of pregnancy |
| Intensity of phosphorylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of phosphorylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | Mass spectrometry, quantitative | 34 to 41 weeks of pregnancy |
| Intensity of phosphorylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of phosphorylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | Mass spectrometry, quantitative | 34 to 41 weeks of pregnancy |
| Intensity of phosphorylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of phosphorylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | Mass spectrometry, quantitative | 34 to 41 weeks of pregnancy |
| Intensity of phosphorylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of phosphorylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | Mass spectrometry, quantitative | 34 to 41 weeks of pregnancy |
| Intensity of ubiquitination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of ubiquitination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | Mass spectrometry, quantitative | 34 to 41 weeks of pregnancy |
| Intensity of ubiquitination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of ubiquitination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | Mass spectrometry, quantitative | 34 to 41 of pregnancy |
| Intensity of ubiquitination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of ubiquitination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | Mass spectrometry, quantitative | 34 to 41 weeks of pregnancy |
| Intensity of ubiquitination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of ubiquitination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | Mass spectrometry, quantitative | 34 to 41 weeks of pregnancy |
| Intensity of citrullination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of citrullination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | Mass spectrometry, quantitative | 34 to 41 weeks of pregnancy |
| Intensity of citrullination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of citrullination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | Mass spectrometry, quantitative | 34 to 41 weeks of pregnancy |
| Intensity of citrullination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of citrullination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | Mass spectrometry, quantitative | 34 to 41 weeks of pregnancy |
| Intensity of citrullination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of citrullination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy | Mass spectrometry, quantitative | 34 to 41 weeks of pregnancy |
| Modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia early on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies. | The presence of methylation, acetylation, phosphorylation, ubiquitination and citrullination in each histone in women developing pre-eclampsia early on will be recorded as YES/NO. | Before 34 weeks of pregnancy |
| Modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia later on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies. | The presence of methylation, acetylation, phosphorylation, ubiquitination and citrullination in each histone in women developing pre-eclampsia later on will be recorded as YES/NO. | 34 to 41 weeks of pregnancy |
| Intensity of modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia early on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies. | Mass spectrometry, quantitative | Before 34 weeks of pregnancy |
| Intensity of modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia later on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies. | Mass spectrometry, quantitative | 34 to 41 weeks of pregnancy |
| ID | Term |
|---|---|
| D011225 | Pre-Eclampsia |
| ID | Term |
|---|---|
| D046110 | Hypertension, Pregnancy-Induced |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided